Introduction {#section4-1753466620905274}
============

The endothelial receptors are known to be critical in vessel maturation and stabilization after birth, which are risk factors for many kinds of respiratory diseases.^[@bibr1-1753466620905274]^ Angiopoietin is one of the members of the vascular growth factor family, which contributes to embryonic and postnatal angiogenesis. Angiopoietin signaling directly interacts with angiogenesis, the process involved in the formation of new arteries and veins.^[@bibr2-1753466620905274]^ It is responsible for disassembling and assembling the endothelial lining of blood vessels. Angiopoietin-2 (Ang-2), a ligand of the endothelial receptor Tie2, blocks Tie2 phosphorylation^[@bibr3-1753466620905274]^ and contributes to vessel destabilization and proinflammatory states.^[@bibr4-1753466620905274],[@bibr5-1753466620905274]^ Acute respiratory distress syndrome (ARDS) is induced by pathological permeability of the epithelium and pulmonary endothelium, which leads to intra-alveolar edema rich in inflammatory mediators and leukocytes.^[@bibr5-1753466620905274][@bibr6-1753466620905274]--[@bibr7-1753466620905274]^ Patients manifest severe oxygenation failure and display a high mortality clinically. They progress to death in approximately 20--40% of cases.^[@bibr8-1753466620905274][@bibr9-1753466620905274]--[@bibr10-1753466620905274]^ Notably, effects of endothelial receptors and changes in Ang-2 levels have been involved in the underlying mechanisms contributing to the link between circulating Ang-2 and the risk of mortality in patients with ARDS.^[@bibr11-1753466620905274],[@bibr12-1753466620905274]^ Indeed, an early prospective cohort study showed that increased plasma Ang-2 levels independently predicts mortality in over 900 patients with acute lung injury (ALI) or ARDS.^[@bibr13-1753466620905274]^ Subsequent studies showed that selective temporal blockade of Ang-2 function greatly improved PaO~2~/FiO~2~, decreased lung protein leak and indices of inflammation, and finally improved overall survival in murine models of ARDS.^[@bibr12-1753466620905274]^ Although a large number of cohort studies in patients with ARDS or ALI further confirmed the prognostic role of circulating Ang-2 levels for ARDS outcome,^[@bibr14-1753466620905274],[@bibr15-1753466620905274]^ some studies failed to display a specific association between Ang-2 level and ARDS prognosis.^[@bibr15-1753466620905274],[@bibr16-1753466620905274]^ Therefore, in this study, we performed a systematic review and meta-analysis of all available studies to quantitatively evaluate the association between baseline circulating Ang-2 and the risk of mortality in patients with ARDS.

Methods {#section5-1753466620905274}
=======

Search strategy {#section6-1753466620905274}
---------------

PubMed, Embase, as well as Cochrane library databases were searched from the inception up to 31 March 2019 for relevant studies without language restriction. Methods used are consistent with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement for reporting systematic reviews and the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.^[@bibr17-1753466620905274]^ [Supplementary materials](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274) display the PRISMA checklist. The search terms used were as follows: PubMed: ((((((("Acute Lung Injury"\[Mesh\]) OR Acute Lung Injuries\[Title/Abstract\]) OR Lung Injuries, Acute\[Title/Abstract\]) OR Lung Injury, Acute\[Title/Abstract\])) OR ((((((((("Respiratory Distress Syndrome, Adult"\[Mesh\]) OR Shock Lung\[Title/Abstract\]) OR Lung, Shock\[Title/Abstract\]) OR ARDS, Human\[Title/Abstract\]) OR ARDSs, Human\[Title/Abstract\]) OR Human ARDS\[Title/Abstract\]) OR Respiratory Distress Syndrome, Acute\[Title/Abstract\]) OR Acute Respiratory Distress Syndrome\[Title/Abstract\]) OR Adult Respiratory Distress Syndrome\[Title/Abstract\]))) AND (("Angiopoietin-2"\[Mesh\]) OR Angiopoietin 2\[Title/Abstract\]). Embase: ('adult respiratory distress syndrome'/exp OR 'acute lung injury'/exp OR 'acute lung injuries': ab,ti OR 'lung injuries, acute':ab,ti OR 'lung injury, acute':ab,ti) AND ('angiopoietin 2'/exp OR 'angiopoietin 2':ab,ti). To identify additional eligible studies, we also screened the references of included papers and published meta-analyses.

Selection criteria {#section7-1753466620905274}
------------------

Criteria of the current systematic review and meta-analysis were as follows: (a) Investigations conducted in human; (b) serum or plasma Ang-2 level was measured at baseline; (c) mortality in patients with ARDS were displayed as the end-points; (d) Odds ratios (OR) with confidence intervals (CI) were shown or estimated for the association between baseline Ang-2 level and mortality in patients with ARDS. Patients were diagnosed according to the American--European Consensus Conference diagnostic criteria for ARDS or the Berlin Definition of ARDS. Acute lung injury was defined with the same criteria except for patients with PaO~2~/FiO~2~ less than 300. We eliminated studies that are animal experiments, case reports, narrative reviews, or present insufficient data for pooling. Two independent reviewers performed the database searching and subsequent review of the literature. Consultation was also launched with a senior investigator to resolve any remaining discrepancies.

Data extraction {#section8-1753466620905274}
---------------

Country of origin, surname of the first author, sample size, year of publication, research design, patients' diseases, gender, age, follow-up period, serum or plasma Ang-2, time-points of Ang-2 measurement, disease outcome, adjustment variables, and ORs with their corresponding 95% CIs were extracted for each potentially included study. The outcome assessed in the meta-analysis was the risk of mortality in patients with ARDS. The data extraction was conducted by two independent investigators *via* a predesigned data extraction form. Divergences were resolved by consensus or by consulting a senior investigator.

Quality evaluation {#section9-1753466620905274}
------------------

The risk of bias for included studies based on study group was evaluated *via* the Newcastle--Ottawa Scale (NOS),^[@bibr18-1753466620905274]^ including group comparability and ascertainment of exposure or outcome. Quality of evidence in GRADE system was assessed *via* Grade Pro 4.04 (designed by Grade Working Group) and the results are displayed in [Supplementary Table S2](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274). Two reviewers independently evaluated the quality of each study.

Statistical analysis {#section10-1753466620905274}
--------------------

ORs and their corresponding CIs were used to evaluate the risk of mortality in patients with ARDS with different levels of Ang-2. The definitions of quartiles of baseline Ang-2 were in line with the original definition in the literature. Heterogeneity among studies was assessed *via* the *I*^2^ statistic, Cochran's *Q* test and *p* value. When subgroup analysis was performed, although some groups had less than five studies, a random-effects model was applied to all meta-analyses for which both fixed-effect and random-effects models were used to calculate pooled ORs. A fixed-effect model was also used when heterogeneity was absent (*I*^2^ = 0%). Potential sources of heterogeneity were explored *via* stratified analysis. A meta-regression model fitted with covariables including country, publishing year, population, follow-up days, samples, design, adjusted covariate, grade scores, and clinical compliance were analyzed to explore potential sources of heterogeneity. In sensitivity analysis, we assessed the influence of each single study on overall estimates. To assess the influence of new studies on overall effects, cumulative meta-analysis according to the year of publication for individual studies was performed. Selective reporting as well as publication bias were examined by visual inspection of the asymmetry of the funnel plot, in which the standard error of log OR was plotted against OR. Begg's and Egger's linear regression tests were performed to determine statistical significance.^[@bibr19-1753466620905274]^ The trim-and-fill approach was utilized to determine the number of additional studies required to overcome potential bias and provide adjusted effects. All statistical analyses were conducted with STATA software, version 15.1 (StataCorp LP, College Station, TX, USA). A two-sided *p* value \< 0.05 was considered statistically significant.

Results {#section11-1753466620905274}
=======

Literature search {#section12-1753466620905274}
-----------------

In total, 278 records from Embase, PubMed, as well as Cochrane Library databases were retrieved. After removing 93 duplicates, the remaining 185 records had their titles and abstracts examined further. Among these papers, 144 were not associated with the theme and 19 were not clinical studies. Full-text review further excluded 12 articles, yielding a sum of 10 studies for the meta-analysis.

Of these studies, one study drew a conclusion about the relationship between Ang-2 and mortality in patients with ARDS but did not provide OR.^[@bibr15-1753466620905274]^ Six studies did not provide ORs with 95% CI.^[@bibr20-1753466620905274][@bibr21-1753466620905274][@bibr22-1753466620905274][@bibr23-1753466620905274][@bibr24-1753466620905274]--[@bibr25-1753466620905274]^ Three studies were from the same database.^[@bibr26-1753466620905274][@bibr27-1753466620905274]--[@bibr28-1753466620905274]^ In addition, another three investigations did not follow the clinical rules.^[@bibr29-1753466620905274][@bibr30-1753466620905274]--[@bibr31-1753466620905274]^ A flow chart describing the process of study selection is displayed in [Figure 1](#fig1-1753466620905274){ref-type="fig"}.

![Flowchart of database search and study identification.\
CI, confidence interval; HR, hazard ratio; OR, odds ratio; RR, risk ratio.](10.1177_1753466620905274-fig1){#fig1-1753466620905274}

Study characteristics {#section13-1753466620905274}
---------------------

The detailed characteristics of the 10 prospective studies published from 2007 to 2018 are shown in [Table 1](#table1-1753466620905274){ref-type="table"}. Among these studies, seven were conducted in the United States,^[@bibr13-1753466620905274],[@bibr16-1753466620905274],[@bibr32-1753466620905274][@bibr33-1753466620905274][@bibr34-1753466620905274][@bibr35-1753466620905274]--[@bibr36-1753466620905274]^ while others were performed in United Kingdom,^[@bibr37-1753466620905274]^ Greece,^[@bibr38-1753466620905274]^ and China.^[@bibr39-1753466620905274]^ Follow-up durations of these studies ranged from 15 to 100 days. Children^[@bibr16-1753466620905274],[@bibr34-1753466620905274]^ and adults^[@bibr13-1753466620905274],[@bibr32-1753466620905274],[@bibr33-1753466620905274],[@bibr35-1753466620905274][@bibr36-1753466620905274][@bibr37-1753466620905274][@bibr38-1753466620905274]--[@bibr39-1753466620905274]^ were both included in this study. Generally, the size of study cohorts varied from 53 to 931 participants, with a total of 3723 subjects included in the final meta-analysis. The outcome reported from these studies was mortality in patients with ARDS. All included studies were displayed as low to high quality, as indicated by individual NOS scores ranging from 4--8.

###### 

Characteristics of included studies.

![](10.1177_1753466620905274-table1)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                              Country   Population   Follow-up\   Male (%)   Age               Assay   Sample   Design   Patients\      Quality\
                                                                                             days                                                                status         score
  ------------------------------------------------------------------- --------- ------------ ------------ ---------- ----------------- ------- -------- -------- -------------- ----------
  Calfee and colleagues^[@bibr13-1753466620905274]^                   USA       Adult        90           53.0       50 ± 16           ELISA   Plasma   PCS      Non-severity   4

  Yehya and colleagues^[@bibr16-1753466620905274]^                    USA       Children     28           50.0       4.1 (0.6--13)     ELISA   Plasma   RCT      Non-severity   4

  Gallagher and colleagues^[@bibr32-1753466620905274]^                USA       Adult        60           48.0       67 ± 17           ELISA   Plasma   PCS      Severity       6

  Calfee and colleagues^[@bibr33-1753466620905274]^                   USA       Adult        90           52.0       51 ± 16           ELISA   Plasma   RCT      Severity       5

  Zinter and colleagues^[@bibr34-1753466620905274]^                   USA       Children     100          55.4       5.2 (1.1--13.2)   ELISA   Plasma   RCT      Severity       7

  Reilly and colleagues^[@bibr35-1753466620905274]^                   USA       Adult        30           58.8       60 (51--69)       ELISA   Plasma   RCT      Severity       7

  Calfee and colleagues^[@bibr36-1753466620905274]^                   USA       Adult        90           N/A        N/A               N/A     Plasma   RCT      Severity       5

  Ganter and colleagues^[@bibr37-1753466620905274]^                   UK        Adult        28           75.0       41 (27--63)       ELISA   Plasma   RCT      Severity       8

  Giamarellos-Bourboulis and colleagues^[@bibr38-1753466620905274]^   Greece    Adult        15           N/A        N/A               ELISA   Serum    RCT      Non-severity   4

  Zhong and colleagues^[@bibr39-1753466620905274]^                    China     Adult        28           66.0       59.2 ± 17.4       ELISA   Plasma   PCS      Severity       5
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ELISA, enzyme-linked immunosorbent assay; PCS, prospective cohort study; RCT, randomized controlled trial; UK, United Kingdom; USA, United States.

Ang-2 and mortality in patients with ARDS {#section14-1753466620905274}
-----------------------------------------

All ten included studies, which included 3723 participants, reported the potential association between circulating blood Ang-2 and risk of mortality in patients with ARDS.^[@bibr13-1753466620905274],[@bibr21-1753466620905274],[@bibr32-1753466620905274][@bibr33-1753466620905274][@bibr34-1753466620905274]--[@bibr35-1753466620905274],[@bibr37-1753466620905274][@bibr38-1753466620905274]--[@bibr39-1753466620905274]^ Meta-analysis showed that elevated blood levels of Ang-2 were independently associated with increased mortality in patients with ARDS (OR 1.56, 95% CI: 1.30--1.89). However, a considerable heterogeneity was noticed among different studies (*I*^2^ = 76.2%, *p* \< 0.001; [Figure 2](#fig2-1753466620905274){ref-type="fig"}). Subsequently, we performed a subgroup analysis to evaluate the potential effects of country, publishing year, population, follow-up days, samples, design, adjusted covariate, quality scores, and clinical compliance on the association between baseline Ang-2 and mortality in patients with ARDS. We found that higher Ang-2 levels were associated with an increase of overall mortality in high-quality papers (OR = 1.68, 95% CI: 1.33--2.13, *I*^2^ = 62.4%) ([Supplementary Figure S4A](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)). Studies of patients with high or low compliance both showed that the *I*^2^ of the bad compliance group decreased from 76.2% to 8.5%, which suggested that compliance is a significant source of heterogeneity ([Supplementary Figure S4B](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)). For sample subgroups, fixed-effect model was used to estimate pooled ORs (serum: OR = 4.00, 95% CI: 1.09--14.70; plasma: OR = 1.49, 95% CI: 1.24-- 1.79). Furthermore, pooled hazard ratios from studies performed in the other countries (OR = 1.51, 95% CI: 1.24--1.85) were not statistically significant, while those in the United States showed a 50% higher risk of mortality in patients with increased Ang-2 levels (OR = 2.41, 95% CI: 0.97-- 5.99). Additional subgroup analyses showed similar increases of mortality risk in studies with different follow-up days (follow-up ⩽30 days: OR = 1.65, 95% CI: 1.14--2.39, *I*^2^ = 74.5%; follow-up \>30 days: OR = 1.55, 95% CI: 1.30--1.86, *I*^2^ = 52.9%). As all included studies have been published within 10 years in this meta-analysis, we checked if the year of publication affected the pooled OR by cumulative analysis ([Supplementary Figure S5](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)). The association of baseline Ang-2 and mortality risk remained after the addition of more recent studies, which was further confirmed by the results of meta-regression for publication year (*p* = 0.187). Fitting other variables, including country, publishing year, population, follow-up days, samples, design, adjusted covariate, quality scores, and clinical compliance into the meta-regression model did not indicate additional sources of heterogeneity ([Table 2](#table2-1753466620905274){ref-type="table"}). Results of sensitivity analysis did not support a certain study impacting the overall outcome significantly ([Supplementary Figure S6](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)). According to the results, no individual study was found responsible for the observed heterogeneity.

![Forest plot (random-effects model) for the association between primary Angiopoietin-2 **(**Ang-2) level or increased Ang-2 level and acute respiratory distress syndrome associated mortality: overall meta-analysis results.\
CI, confidence interval; OR, odds ratio.](10.1177_1753466620905274-fig2){#fig2-1753466620905274}

###### 

Stratified analysis of pooled odds ratio risks of ARDS associated mortality.

![](10.1177_1753466620905274-table2)

  Stratified analysis      Pooled HR (95% CI)   Heterogeneity                               Meta regression (*p*-value)
  ------------------------ -------------------- ------------------------------------------- -----------------------------
  Country                  0.501                                                            
   Non-USA                 2.41 (0.97--5.99)    *Q* = 7.74, *p* = 0.021, *I*^2^ = 74.2%     
   USA                     1.51 (1.24--1.85)    *Q* = 28.87, *p* \< 0.001, *I*^2^ = 76.2%   
  Follow-up days           0.782                                                            
   ⩽30                     1.65 (1.14--2.39)    *Q* = 15.69, *p* = 0.003, *I*^2^ = 74.5%    
   \>30                    1.55 (1.30--1.86)    *Q* = 8.48, *p* = 0.075, *I*^2^ = 52.9%     
  Publishing year          0.187                                                            
   Before 2011             2.20 (1.28--3.79)    *Q* = 12.00, *p* = 0.007, *I*^2^ = 75.0%    
   After 2011              1.41 (1.16--1.71)    *Q* = 19.93, *p* \< 0.001, *I*^2^ = 74.9%   
  Population               0.044                                                            
   ARDS/ALI                1.60 (1.33--1.90)    *Q* = 15.91, *p* = 0.026, *I*^2^ = 56.0%    
   ARDS/ALI (children)     1.70 (0.61--4.76)    *Q* = 4.30, *p* = 0.038, *I*^2^ = 76.7%     
  Samples                  0.193                                                            
   Plasma                  1.49 (1.24--1.79)    *Q* = 31.56, *p* \< 0.001, *I*^2^ = 77.8%   
   Serum                   4.00 (1.09--14.70)   ---                                         
  Adjustment               0.495                                                            
   Adjusted                1.89 (1.20--3.20)    *Q* = 7.65, *p* = 0.022, *I*^2^ = 73.9%     
   Non-Adjusted            1.48 (1.20--1.81)    *Q* = 25.69, *p* \< 0.001, *I*^2^ = 76.6%   
  Quality score            0.360                                                            
   \>4                     1.68 (1.33--2.13)    *Q* = 15.95, *p* = 0.014, *I*^2^ = 62.4%    
   ⩽4                      1.38 (1.00--1.92)    *Q* = 12.58, *p* = 0.002, *I*^2^ = 84.1%    
  Compliance of patients   0.323                                                            
   Good                    1.89 (1.33--2.68)    *Q* = 32.43, *p* \< 0.001, *I*^2^ = 84.6%   
   Bad                     1.38 (1.20--1.58)    *Q* = 3.28, *p* = 0.351, *I*^2^ = 8.5%      
  Study design             0.198                                                            
   RCT                     1.92 (1.38--2.66)    *Q* = 32.96, *p* \< 0.001, *I*^2^ = 81.8%   
   PCS                     1.40 (1.23--1.59)    *Q* = 1.77, *p* = 0.412, *I*^2^ = 0         

ALI, acute lung injury; ARDS, acute respiratory distress syndrome; HR, hazard ratio; PCS, prospective cohort study; RCT, randomized controlled trial; USA, United States.

The funnel plot showed obvious asymmetry, indicating the presence of publication bias ([Supplementary Figure S1](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)**)**. Application of a trim-and-fill model suggested that three more studies may be required to eliminate the publication bias, although the pooled effect was markedly different ([Supplementary Figure S2A](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274) and [S2B](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)). Nonetheless, statistics using the Egger's (*p* = 0.599) and Begg's (*p* = 0.371) regression tests did not show a significant bias in publication ([Supplementary Figure S3A](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274) and [S3B](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)). We also used the standard 'risk of bias' tool and NOS to evaluate bias ([Supplementary Figure S7A](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274) and[S7B](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274); [Table 1](#table1-1753466620905274){ref-type="table"} and [Supplementary Table S3](https://journals.sagepub.com/doi/suppl/10.1177/1753466620905274)).

Discussion {#section15-1753466620905274}
==========

In this study, by pooling the data from 10 available prospective cohort studies incorporating 3723 participants, we found that higher circulating Ang-2 at baseline was independently associated with a 56% increase in the risk of mortality in patients with ARDS. Although significant heterogeneity was detected, subsequent subgroup and meta-analyses found that the quality scores of papers may be responsible for the heterogeneity. Characteristics of country, publishing year, population, follow-up days, samples, design, adjusted covariate, and clinical compliance had few significant effects on the association between Ang-2 and the risk of mortality in patients with ARDS. These results suggest that participants with higher baseline Ang-2 were at a higher risk of future risk of mortality in patients with ARDS. Future studies are needed to determine if circulating Ang-2 confers prognostic efficacy for ARDS.

The function of endothelial cells (ECs) is mediated by the competitive binding of EC growth factors during angiogenesis. Ang-2, a ligand of endothelial receptor Tie2, is expressed on ECs primarily.^[@bibr40-1753466620905274],[@bibr41-1753466620905274]^ Ang-1, produced by pericytes, smooth muscle cells, as well as fibroblasts, is found on the extracellular matrix. Ang-1/Tie2 binding is thought to be anti-inflammatory and promote vessel stabilization, prosurvival and antipermeability signaling through phosphorylation of Tie2.^[@bibr42-1753466620905274]^ In contrast, activated ECs rapidly release stored preformed Ang-2 in an autocrine response. Ang-2/Tie2 binding is believed to induce vessel destabilization, pulmonary leakage and inflammation.^[@bibr43-1753466620905274],[@bibr44-1753466620905274]^ Previous clinical investigations have reported elevated EC growth factor, Ang-2, in the peripheral blood from ARDS patients.^[@bibr26-1753466620905274],[@bibr37-1753466620905274],[@bibr45-1753466620905274]^ The shock/sepsis model for the development of ARDS demonstrated effective reduction in indices of inflammation and lung tissue injury following small interfering RNA inhibition of Ang-2 protein synthesis.^[@bibr45-1753466620905274]^ While this method is useful in identifying potential target proteins for therapeutic intervention, similar usage is not currently feasible for treating ARDS in the human patient population.

Nevertheless, the results on the link between Ang-2 level and risk of mortality of patients with ARDS remain limited and inconsistent. For instance, Ang-2 exhibited no significant predictive value on mortality in an observational cohort including 931 patients with ARDS.^[@bibr13-1753466620905274]^ A similar result was obtained from a more recent US study in patients with ARDS.^[@bibr16-1753466620905274]^ More intriguingly, inhibition of Ang-2 confers significant protection against ARDS rather than predisposing to deleterious outcome.^[@bibr45-1753466620905274]^ To the best of our knowledge, ours is the first systematic review and meta-analysis exploring the prognostic value of Ang-2 in ARDS that has been published so far. Results of our study further confirmed that higher Ang-2 at baseline was associated with an increased risk of mortality in patients with ARDS. Moreover, our subsequent subgroup analyses found that the vast disagreement among studies may attribute to various aspects, including quality scores (\>4 and ⩽4) and compliance of patients (good and bad). Good management of patients may be found in studies with a rigorous design. Also, patients are prone to obey the management in large medical centers. Compliance in our meta-analysis is a comprehensive assessment based on the previous factors. What's more, only studies conducted in the US exhibited a significant overall OR for the high Ang-2 effect on mortality. In spite of this, studies focused on children did not suggest a correlation between increased Ang-2 and a higher risk of mortality in patients with ARDS with statistical significance. Therefore, the result remains uncertain given the limited number of studies, and further studies with larger sample sizes are needed to confirm our results.

Strength and limitations {#section16-1753466620905274}
------------------------

Our study demonstrated the potential prognostic power of Ang-2 in a variety of populations with ARDS. To our knowledge, this is the first meta-analysis that shows a positive correlation between a high Ang-2 level and an adverse ARDS outcome. In this study, we included only prospective cohorts and followed the PRISMA and MOOSE guidelines. Potential sources of heterogeneity were explored using different methods, and trim-and-fill strategy was applied to solve the possibility of publication bias. All of the previous aspects added to the power of the study.

Our study also has potential limitations, which should be considered when interpreting the results. First, studies that did not provide sufficient data for pooling were excluded from the meta-analysis, which may raise the risk of bias in the overall effects by Ang-2. A considerable risk of publication bias was identified for the association between high Ang-2 and mortality in patients with ARDS, leading to a dubitative conclusion on the relationship. Second, considerable heterogeneities existed in baseline clinical characteristics including age, gender, and race across individual studies. In addition, uncontrolled confounding factors including basic diseases and genetic variation may significantly affect the concentration of Ang-2. Inclusion of those studies without comprehensive adjustment may yield inaccurate effects. Third, the lack of continuous data made it difficult to draw a quantitative result on the differences of Ang-2 between subjects with and without events. Finally, results of our meta-analysis of observational studies could only provide the potential temporal association between increased circulating Ang-2 and the subsequent risk of mortality in patients with ARDS. Whether increased Ang-2 was causative to a poor ARDS outcome deserves further investigation.

Conclusion {#section17-1753466620905274}
==========

Participants with higher baseline Ang-2 were at a higher risk for future risk of mortality in patients with ARDS. Further large scale prospective cohorts or even interventional studies are warranted to evaluate the diagnostic power of Ang-2 and its causative role on ARDS outcome.
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